Gregg Williams Buys 1,587,301 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,587,301 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the purchase, the director owned 34,531,785 shares of the company’s stock, valued at approximately $43,510,049.10. This represents a 4.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Gregg Williams also recently made the following trade(s):

• On Wednesday, April 15th, Gregg Williams bought 1,587,301 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.26 per share, with a total value of $1,999,999.26.
• On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The shares were purchased at an average price of $1.07 per share, for a total transaction of $1,685,497.17.

Vivani Medical Stock Down 2.6%

Shares of NASDAQ VANI opened at $1.14 on Tuesday. Vivani Medical, Inc. has a twelve month low of $0.92 and a twelve month high of $1.92. The business’s 50 day moving average price is $1.18 and its two-hundred day moving average price is $1.29. The company has a market cap of $98.31 million, a PE ratio of -2.85 and a beta of 2.35.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). As a group, research analysts anticipate that Vivani Medical, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price target on Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.50.

Hedge Funds Weigh In On Vivani Medical

Hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL bought a new position in shares of Vivani Medical during the fourth quarter worth about $1,127,000. Geode Capital Management LLC boosted its holdings in Vivani Medical by 29.6% in the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after acquiring an additional 105,398 shares during the last quarter. State Street Corp increased its position in Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after purchasing an additional 16,070 shares during the period. Marshall Wace LLP acquired a new stake in Vivani Medical during the 4th quarter valued at approximately $174,000. Finally, Renaissance Technologies LLC raised its holdings in Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after purchasing an additional 53,127 shares during the last quarter. Institutional investors and hedge funds own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.